huMesoCART

N/A

Report date: 2025/06/20 20:01:04

Base Information

Drug NamehuMesoCART
Drug Alias Nameautologous huCART-meso T-cell therapy (University of Pennsylvania/Novartis)anti-mesothelin CAR T-cell therapy (University of Pennsylvania/Novartis)huCART-meso cellsMSLN-12MSLN-18 +[12] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMesothelin modulatorsT lymphocytes stimulantsImmunostimulants
TargetsMesothelin
Therapy Area/IndicationsMetastatic breast cancerFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesNovartis AgUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A